MEDICAL_COSMETICS_LIMITED - Accounts


Company registration number 05363175 (England and Wales)
MEDICAL COSMETICS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023
PAGES FOR FILING WITH REGISTRAR
MEDICAL COSMETICS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
4 - 9
MEDICAL COSMETICS LIMITED
BALANCE SHEET
AS AT
31 MARCH 2023
31 March 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
4
109,448
121,549
Current assets
Stocks
7,500
7,500
Debtors
5
83,536
114,463
Cash at bank and in hand
31,747
4,983
122,783
126,946
Creditors: amounts falling due within one year
6
(114,679)
(123,457)
Net current assets
8,104
3,489
Total assets less current liabilities
117,552
125,038
Provisions for liabilities
(7,168)
(7,168)
Net assets
110,384
117,870
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
110,383
117,869
Total equity
110,384
117,870

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

MEDICAL COSMETICS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2023
31 March 2023
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 30 December 2023
Dr A Siddiqi
Director
Company Registration No. 05363175
MEDICAL COSMETICS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2023
- 3 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 April 2021
1
(21,153)
(21,152)
Year ended 31 March 2022:
Profit and total comprehensive income for the year
-
154,022
154,022
Dividends
-
(15,000)
(15,000)
Balance at 31 March 2022
1
117,869
117,870
Year ended 31 March 2023:
Profit and total comprehensive income for the year
-
92,514
92,514
Dividends
-
(100,000)
(100,000)
Balance at 31 March 2023
1
110,383
110,384
MEDICAL COSMETICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023
- 4 -
1
Accounting policies
Company information

Medical Cosmetics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Broad House, 8 Regan Way, Chetwynd Business Park, Chilwell, Nottingham, NG9 6RZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings Leasehold
2% straight line
Plant and machinery
25% pa reducing balance
Fixtures, fittings & equipment
25% pa reducing balance
MEDICAL COSMETICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 5 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

MEDICAL COSMETICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 6 -
1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

MEDICAL COSMETICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
1
Accounting policies
(Continued)
- 7 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

MEDICAL COSMETICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 8 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
8
8
4
Tangible fixed assets
Land and buildings Leasehold
Plant and machinery
Fixtures, fittings & equipment
Total
£
£
£
£
Cost
At 1 April 2022 and 31 March 2023
95,338
99,946
39,251
234,535
Depreciation and impairment
At 1 April 2022
11,441
75,868
25,678
112,987
Depreciation charged in the year
1,907
6,020
4,173
12,100
At 31 March 2023
13,348
81,888
29,851
125,087
Carrying amount
At 31 March 2023
81,990
18,058
9,400
109,448
At 31 March 2022
83,897
24,079
13,573
121,549
5
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
5,671
5,669
Corporation tax recoverable
2,992
2,992
Other debtors
74,873
105,802
83,536
114,463
MEDICAL COSMETICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023
- 9 -
6
Creditors: amounts falling due within one year
2023
2022
£
£
Bank loans
48,750
71,250
Trade creditors
4,311
8,472
Corporation tax
60,452
40,750
Other taxation and social security
-
0
495
Other creditors
1,166
2,490
114,679
123,457
8
Directors' transactions

Dividends totalling £100,000 (2022 - £15,000) were paid in the year in respect of shares held by the company's directors.

The director has a loan of £72,638 which has an interest rate of 2% pa.

2023-03-312022-04-01false30 December 2023CCH SoftwareCCH Accounts Production 2023.300No description of principal activityDr A SiddiqiMr F Siddiqifalse053631752022-04-012023-03-31053631752023-03-31053631752022-03-3105363175core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-03-3105363175core:PlantMachinery2023-03-3105363175core:FurnitureFittings2023-03-3105363175core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-03-3105363175core:PlantMachinery2022-03-3105363175core:FurnitureFittings2022-03-3105363175core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3105363175core:CurrentFinancialInstrumentscore:WithinOneYear2022-03-3105363175core:CurrentFinancialInstruments2023-03-3105363175core:CurrentFinancialInstruments2022-03-3105363175core:ShareCapital2023-03-3105363175core:ShareCapital2022-03-3105363175core:RetainedEarningsAccumulatedLosses2023-03-3105363175core:RetainedEarningsAccumulatedLosses2022-03-3105363175core:ShareCapital2021-03-3105363175core:RetainedEarningsAccumulatedLosses2021-03-31053631752021-03-3105363175bus:Director12022-04-012023-03-3105363175core:RetainedEarningsAccumulatedLosses2021-04-012022-03-31053631752021-04-012022-03-3105363175core:RetainedEarningsAccumulatedLosses2022-04-012023-03-3105363175core:LandBuildingscore:LongLeaseholdAssets2022-04-012023-03-3105363175core:PlantMachinery2022-04-012023-03-3105363175core:FurnitureFittings2022-04-012023-03-3105363175core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-03-3105363175core:PlantMachinery2022-03-3105363175core:FurnitureFittings2022-03-31053631752022-03-3105363175core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-04-012023-03-3105363175core:WithinOneYear2023-03-3105363175core:WithinOneYear2022-03-3105363175bus:PrivateLimitedCompanyLtd2022-04-012023-03-3105363175bus:SmallCompaniesRegimeForAccounts2022-04-012023-03-3105363175bus:FRS1022022-04-012023-03-3105363175bus:AuditExemptWithAccountantsReport2022-04-012023-03-3105363175bus:CompanySecretary12022-04-012023-03-3105363175bus:FullAccounts2022-04-012023-03-31xbrli:purexbrli:sharesiso4217:GBP